statistiche ricercatore

MORA, BARBARA

Distribuzione geografica

Continente	#
NA - Nord America	2.131
EU - Europa	984
AS - Asia	255
SA - Sud America	6
OC - Oceania	2
Continente sconosciuto - Info sul continente non disponibili	1
Totale	3.379

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	2.122
IT - Italia	515
UA - Ucraina	137
SE - Svezia	101
TR - Turchia	87
IE - Irlanda	67
VN - Vietnam	62
DE - Germania	49
SG - Singapore	46
CN - Cina	42
GB - Regno Unito	33
FI - Finlandia	23
RU - Federazione Russa	21
CA - Canada	9
CZ - Repubblica Ceca	9
JP - Giappone	8
NL - Olanda	5
BE - Belgio	4
FR - Francia	4
CL - Cile	3
ES - Italia	3
TH - Thailandia	3
BD - Bangladesh	2
BR - Brasile	2
GR - Grecia	2
HK - Hong Kong	2
HU - Ungheria	2
LT - Lituania	2
PL - Polonia	2
AL - Albania	1
AR - Argentina	1
AT - Austria	1
AU - Australia	1
EU - Europa	1
IN - India	1
MD - Moldavia	1
MY - Malesia	1
NO - Norvegia	1
NZ - Nuova Zelanda	1
RO - Romania	1
SA - Arabia Saudita	1
Totale	3.379

Salva come PNG Salva come JPEG

Città	#
Milan	375
Fairfield	323
Woodbridge	226
Ashburn	181
Houston	162
Chandler	150
Seattle	149
Jacksonville	121
Wilmington	121
Cambridge	116
Ann Arbor	113
Nyköping	77
Princeton	65
Dublin	64
Izmir	48
Singapore	46
Boardman	41
Dearborn	38
Dong Ket	33
San Diego	31
Como	22
Rome	22
Ogden	20
Redmond	18
London	15
Kocaeli	13
Helsinki	10
Brno	9
Munich	8
Washington	8
Santa Clara	7
Toronto	7
Beijing	6
Frankfurt am Main	6
New York	5
Brussels	4
Chicago	4
Hefei	4
Kilburn	4
Kunming	4
Redwood City	4
San Francisco	4
Tokyo	4
Amsterdam	3
Gavirate	3
Nanchang	3
Nanjing	3
Norwalk	3
San Jose	3
Busto Arsizio	2
Dallas	2
Dhaka	2
Espoo	2
Hanoi	2
Mountain View	2
Ottawa	2
Piombino	2
Prescot	2
Seriate	2
Shanghai	2
Vanzaghello	2
Yokohama	2
Zhengzhou	2
Abbadia Lariana	1
Bangkok	1
Baotou	1
Budapest	1
Casorezzo	1
Central	1
Chaoyang	1
Charleston	1
Charlotte	1
Chisinau	1
Chiswick	1
Cupertino	1
Fayetteville	1
Fiesole	1
Fuzhou	1
Gallarate	1
Genoa	1
Graz	1
Greenwich	1
Guangzhou	1
Guiyang	1
Gurgaon	1
Harbin	1
Hebei	1
Hong Kong	1
Hounslow	1
Huzhou	1
Inglewood	1
Kuala Lumpur	1
Lappeenranta	1
Leawood	1
Los Angeles	1
Madrid	1
Marchirolo	1
Miami Beach	1
New Bedfont	1
Ningbo	1
Totale	2.771

Salva come PNG Salva come JPEG

Nome	#
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts	187
Looking for CALR mutations in familial myeloproliferative neoplasms	174
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis	165
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project	152
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion	151
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients	150
It is time to change thrombosis risk assessment for PV and ET?	146
Developments in diagnosis and treatment of essential thrombocythemia	143
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients	141
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group	141
New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms	129
Prognostication in myelofi-brosis	124
Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis	119
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project	114
Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenström macroglobulinemia	110
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation	105
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia	99
Therapy of polycythemia vera: Is it time to change?	94
Polycythemia vera: From new, modified diagnostic criteria to new therapeutic approaches	88
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients	87
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation	72
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses	70
Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection	70
Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi	67
Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma	60
Increased plasma levels of lncrnas linc01268, gas5 and malat1 correlate with negative prognostic factors in myelofibrosis	58
Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: results of a prospective cohort study of 365 patients	57
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study	55
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis	53
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence	53
Is there a gender effect in polycythemia vera?	50
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies	47
Second primary malignancies in ruxolitinib-treated myelofibrosis: Real-world evidence from 219 consecutive patients	46
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis	46
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis	37
Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas	13
Totale	3.473

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	16.833
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	16.833

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	385	0	0	0	0	0	73	95	75	62	34	16	30
2020/2021	782	22	48	116	46	114	65	42	63	75	56	62	73
2021/2022	331	50	16	2	15	11	22	16	21	26	87	19	46
2022/2023	473	33	13	75	43	36	102	2	56	75	13	9	16
2023/2024	618	91	94	92	115	133	40	7	4	25	2	5	10
2024/2025	188	15	3	79	43	23	25	0	0	0	0	0	0
Totale													3.473